Livzon Pharmaceutical Group Inc. (SHE:000513)

SHE:000513 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Jan 1, 2022	Jan 1, 2021
Operating Revenue	11,701	12,326	12,524	11,928	10,463
Other Revenue	111.73	104.45	105.89	135.88	57.34
Revenue	11,812	12,430	12,630	12,064	10,520
Revenue Growth (YoY)	-4.97%	-1.58%	4.69%	14.67%	12.10%
Cost of Revenue	4,249	4,772	4,577	4,309	3,744
Gross Profit	7,564	7,658	8,053	7,754	6,777
Selling, General & Admin	3,869	4,255	4,545	4,548	3,740
Research & Development	1,033	1,335	1,427	1,146	884.1
Other Operating Expenses	120.33	133.07	143.97	135.87	122.94
Operating Expenses	5,027	5,736	6,121	5,837	4,747
Operating Income	2,536	1,921	1,932	1,917	2,029
Interest Expense	-88.61	-102.09	-97.55	-84	-25.31
Interest & Investment Income	265.34	429.98	359.25	251.81	323.19
Currency Exchange Gain (Loss)	0.94	10.23	56.68	-4.28	-41.56
Other Non Operating Income (Expenses)	-6.98	-4.42	-6.37	-4.01	-5.89
EBT Excluding Unusual Items	2,707	2,255	2,244	2,077	2,280
Gain (Loss) on Sale of Investments	-15.44	-25.65	-75.27	-23.03	8.81
Gain (Loss) on Sale of Assets	45.2	-0.17	0.86	7.03	-1.07
Asset Writedown	-19.86	-2.43	-13.99	-6.15	-6.9
Other Unusual Items	89.08	155.76	174.68	191.12	208.76
Pretax Income	2,806	2,383	2,331	2,246	2,489
Income Tax Expense	501.66	485.07	374.97	293.59	358.11
Earnings From Continuing Operations	2,304	1,898	1,956	1,952	2,131
Minority Interest in Earnings	-243.39	56.05	-46.17	-176.42	-416.42
Net Income	2,061	1,954	1,909	1,776	1,715
Net Income to Common	2,061	1,954	1,909	1,776	1,715
Net Income Growth	5.50%	2.32%	7.53%	3.54%	31.62%
Shares Outstanding (Basic)	920	929	935	935	936
Shares Outstanding (Diluted)	920	931	936	936	939
Shares Change (YoY)	-1.10%	-0.56%	-0.04%	-0.25%	0.41%
EPS (Basic)	2.24	2.10	2.04	1.90	1.83
EPS (Diluted)	2.24	2.10	2.04	1.90	1.83
EPS Growth	6.64%	2.94%	7.47%	3.73%	31.66%
Free Cash Flow	2,409	2,428	1,833	593.23	1,514
Free Cash Flow Per Share	2.62	2.61	1.96	0.63	1.61
Dividend Per Share	1.100	1.350	1.600	1.300	1.250
Dividend Growth	-18.52%	-15.63%	23.08%	4.00%	8.70%
Gross Margin	64.03%	61.61%	63.76%	64.28%	64.41%
Operating Margin	21.47%	15.46%	15.30%	15.89%	19.29%
Profit Margin	17.45%	15.72%	15.12%	14.72%	16.30%
Free Cash Flow Margin	20.39%	19.54%	14.51%	4.92%	14.39%
EBITDA	3,086	2,740	2,563	2,342	2,421
EBITDA Margin	26.12%	22.05%	20.29%	19.41%	23.01%
D&A For EBITDA	549.3	818.8	630.56	425.02	391.69
EBIT	2,536	1,921	1,932	1,917	2,029
EBIT Margin	21.47%	15.46%	15.30%	15.89%	19.29%
Effective Tax Rate	17.88%	20.36%	16.09%	13.07%	14.38%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.